论文部分内容阅读
通过在亚洲(越南和孟加拉国)和撒哈拉以南的非洲(加纳、肯尼亚和马里)两地做随机、有安慰剂对照的现场试验,对TotaTeq这种五价轮状病毒疫苗(PRV)的预防儿童轮状病毒胃肠炎(RVGE)的效果做了评估。结果显示,在多国的试验中,马里现场获得了保护力结果。我们将约6、10和14周龄的婴儿以1:1的比例随机分配,分别服用3剂PRV或安慰剂。通过当地的健康中心和家仿观察,胃肠炎发作被有效遏制。最重要的研究结果是:在第三次服苗14 d后,利用Vesikari临床评分系统评得的分数如果≥11,则被定义为严重的轮状病毒胃肠炎(RVGE)。其他效果分析包括在接种后的第一年和第二年中抵抗严重RVGE的能力,以及接种至少一剂疫苗的效果。
Prevention of TotaTeq, a pentavalent rotavirus vaccine (PRV), through a randomized placebo-controlled field trial in Asia (Vietnam and Bangladesh) and sub-Saharan Africa (Ghana, Kenya and Mali) The effectiveness of children with rotavirus gastroenteritis (RVGE) was assessed. The results showed that in the multinational trials, the protection force was obtained on-site in Mali. We randomized infants around 6, 10, and 14 weeks of age in a 1: 1 ratio to taking 3 doses of PRV or placebo. Gastroenteritis seizures were effectively contained through local health centers and home visits. The most important findings are: Severe rotavirus gastroenteritis (RVGE) was defined as a score of ≥11 with the Vesikari clinical scoring system after 14 days of the third dose of vaccine. Other efficacy analyzes include the ability to fight severe RVGE in the first and second year after vaccination, as well as the effect of at least one dose of vaccine.